Rowena Chu drives biotech commercialization across oncology and genomics

Influential Women is featuring Rowena Chu, a biotech leader with more than a decade of experience in client success, commercialization and strategic partnerships. Her work spans oncology, genomics and molecular diagnostics, with a focus on health equity, women in STEM and responsible use of AI in healthcare. Why it matters: - Rowena Chu’s work sits at the intersection of scientific innovation and business adoption, where complex biotech tools have to prove value in the market. - Her focus on health equity links commercialization work with broader access to screening, diagnostics and preventative care. - Chu also points to AI as a growing force in biomedical research and healthcare delivery, with potential to improve diagnosis, drug discovery and personalized treatment. What happened: - Influential Women is featuring Rowena Chu, a biotech leader based in Santa Clara, California. - Chu has more than a decade of experience in client success, commercialization and strategic partnerships across oncology, genomics and molecular diagnostics. - Chu’s career path moved from molecular biology into commercial and client-facing leadership roles. - Chu began at SRI, where she worked on government-funded infectious disease research. - Chu now works at the intersection of B2B biopharma partnerships, downstream marketing and go-to-market execution. The details: - Chu has worked with Sales, Marketing, Product and Field Applications teams to drive adoption of genomics and next-generation sequencing technologies. - Her scope has included customer onboarding, lifecycle strategy and enterprise engagement. - Chu has supported academic medical centers, biotech organizations and large commercial clients. - Chu helped commercialize NGS and multi-omics platforms. - Chu developed customer-facing messaging frameworks and enablement programs aimed at long-term product use and customer success. - Chu is known for translating technical scientific workflows into value propositions that resonate with researchers, clinicians and executives. - Chu has built a leadership style centered on clarity, accountability and collaboration. - Chu has supported initiatives with Susan G. Komen to expand access to preventative screenings in underserved populations. - Chu also contributes to mission-driven organizations such as St. Jude. - Chu said mentorship, resilience and purpose have shaped her career. - Chu said her son is a major source of motivation. - Chu said her mentors told her to remember her worth and abilities. - Chu advises young women in biotech to stay grounded in purpose, trust their potential and seek mentorship. - Chu says setbacks should be treated as part of the learning process, not as proof of inadequacy. - Chu lists conviction, mentorship and well-being as core values. - Chu also enjoys professional baking, knitting and other hands-on crafts. - Chu’s award-winning apple pies have received recognition. Between the lines: - Chu’s profile reflects a broader shift in biotech toward leaders who can bridge science, commercial strategy and customer adoption. - Her emphasis on women in STEM and underserved communities suggests that her definition of impact extends beyond revenue and product launches. - Her comments on AI point to a familiar industry tension: faster analysis and discovery bring promise, but only if the benefits reach more than a narrow group of patients and providers. What’s next: - Chu says the industry still needs stronger mentorship pipelines for women in STEM. - Chu says better access to early screening, diagnostics and preventative services remains a priority. - Chu sees continued opportunity for responsible AI to support clinicians and researchers. - Chu’s work appears likely to keep focusing on commercialization, partnership building and equity-driven healthcare access. The bottom line: - Rowena Chu is positioning biotech commercialization as both a growth function and a path to broader patient impact.